NCT04613297 (HLA-G-COVID) is a NA clinical trial of Baseline and during hospitalization blood samples in Covid19, sponsored by Hopital Foch.

Who is sponsoring NCT04613297?

NCT04613297 is sponsored by Hopital Foch.

What drugs are being tested in NCT04613297?

Interventions in NCT04613297: Baseline and during hospitalization blood samples, Baseline blood sample.

Is NCT04613297 still recruiting?

NCT04613297 is currently completed. Last updated 3 August 2022.

Last reviewed 2022-08-03 · How we verify

NCT04613297: HLA-G-COVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment

Completed NA Last updated 3 August 2022

What this trial tests

NA trial testing Baseline and during hospitalization blood samples in Covid19 in 91 participants. Completed in 19 July 2022.

Timeline

19 October 2020

Primary endpoint
19 July 2022

19 July 2022

Quick facts

Lead sponsor	Hopital Foch
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	91
Start date	19 October 2020
Primary completion	19 July 2022
Estimated completion	19 July 2022
Sites	1 location across France

Drugs / interventions tested

Baseline and during hospitalization blood samples
Baseline blood sample

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Hopital Foch — full company profile →

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the research is to study the immune checkpoint linked to the HLA-G molecule in the dysregulation of the control of COVID-19 infection.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Perspective of HLA-G Induced Immunosuppression in SARS-CoV-2 Infection.
Lin A, Yan WH. · · 2021 · cited 22× · PMID 34938296 · DOI 10.3389/fimmu.2021.788769
Association of <i>HLA-G</i> 3'UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer.
Scarabel L, Polesel J, De Mattia E, Buonadonna A, et al · · 2022 · cited 6× · PMID 36559230 · DOI 10.3390/pharmaceutics14122737

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Hopital Foch trials

Trials by the same sponsor.

NCT06980844 — Interpretation of the Role of Eosinophils in Diffuse Interstitial Pneumopathies · NA · not yet recruiting
NCT06757244 — DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer · Phase 2 · recruiting
NCT06631794 — Evaluation of the Impact of a HPV Vaccination Talk with Third Grade Students · not yet recruiting
NCT06533436 — Clinical and Economic Comparison of 2 Methods of Intubation Tube Fixation : AnchorFastTM Versus Current Cord Fixation · NA · recruiting
NCT06476002 — Analysis of the Understanding of the French Version of the Vulvar Pain Assessment Questionnaire · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04613297 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hopital Foch
Last refreshed: 3 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04613297.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing